Literature DB >> 1520543

Mapping of immunodominant epitopes of the HIV-1 and HIV-2 integrase proteins by recombinant proteins and synthetic peptides.

C Vinga-Martins1, T Schneider, A Werno, W Roenspeck, G Pauli, N Mueller-Lantzsch.   

Abstract

Different parts of the human immunodeficiency virus type 1 and type 2 (HIV-1 and HIV-2) integrase proteins were expressed as TrpE fusion proteins in Escherichia coli and used to screen human sera. In the immunoblot, all HIV/integrase-positive human sera tested reacted with the carboxy-terminal third of the integrase protein. Furthermore, they crossreacted with the same part of the heterologous protein. Half (50%) of the HIV-1/integrase-positive sera additionally detected antigenic epitopes in the amino-terminal third of the HIV-1 protein. Two of the recombinant proteins were used to generate polyclonal rabbit sera, which react with type-common epitopes of both integrase proteins. To map the B-cell epitopes of the HIV integrase proteins in more detail, overlapping decapeptides representing the entire integrase proteins of HIV-1 and HIV-2 were synthesized and used in a pin-based oligopeptide ELISA to scan human sera. This method can define three potential immunogenic epitopes of the HIV-1 integrase and one potential epitope of the HIV-2 integrase. The immunodominant epitopes of the HIV-1 integrase, one localized in the amino-terminal (IDKAQDEHEKYHSNWRAM), one in the central (QMAVFIHNFKRKGGIGGY), and one in the carboxy-terminal (AVVIQDNSDIKVVPRRK) part of the protein were synthesized as oligopeptides and used to test a larger panel of human sera in ELISA (156 HIV-1+ sera and 104 HIV-1- sera). The amino- and the carboxy-terminal epitopes were of equivalent reactivity, while the central part of the HIV-1 integrase seems to be less immunogenic. Nearly 90% of the HIV-1/integrase-positive human sera could be detected by a combination of these three peptides.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1520543     DOI: 10.1089/aid.1992.8.1301

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  6 in total

1.  Monoclonal antibodies against human immunodeficiency virus type 1 integrase: epitope mapping and differential effects on integrase activities in vitro.

Authors:  B M Nilsen; I R Haugan; K Berg; L Olsen; P O Brown; D E Helland
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

2.  Monoclonal antibodies against Rous sarcoma virus integrase protein exert differential effects on integrase function in vitro.

Authors:  B Müller; D Bizub-Bender; M D Andrake; K S Jones; A M Skalka
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

3.  Expression of a processed and a non-processed form of the integrase protein of HIV-1 in the baculovirus system.

Authors:  B Rodner; C Vinga-Martins; N Müller-Lantzsch
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

4.  Inhibition of human immunodeficiency virus type 1 integrase by the Fab fragment of a specific monoclonal antibody suggests that different multimerization states are required for different enzymatic functions.

Authors:  E V Barsov; W E Huber; J Marcotrigiano; P K Clark; A D Clark; E Arnold; S H Hughes
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

5.  Human immunodeficiency virus type 1 integrase mutants retain in vitro integrase activity yet fail to integrate viral DNA efficiently during infection.

Authors:  A D Leavitt; G Robles; N Alesandro; H E Varmus
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

6.  Peptide design by artificial neural networks and computer-based evolutionary search.

Authors:  G Schneider; W Schrödl; G Wallukat; J Müller; E Nissen; W Rönspeck; P Wrede; R Kunze
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.